keyword
MENU ▼
Read by QxMD icon Read
search

albuvirtide

keyword
https://www.readbyqxmd.com/read/27906013/combination-of-long-acting-hiv-fusion-inhibitor-albuvirtide-and-lpv-r-showed-potent-efficacy-in-hiv-1-patients
#1
Hongwei Zhang, Ronghua Jin, Cheng Yao, Tong Zhang, Meixia Wang, Wei Xia, Haiyan Peng, Xiaojuan Wang, Rongjian Lu, Changjin Wang, Dong Xie, Hao Wu
BACKGROUND: Long acting antiretroviral drugs represent a promising approach for chronic treatment of HIV infection. Here, we study the efficacy and safety of albuvirtide (ABT), an HIV-1 fusion inhibitor with a half life of 11-12 days in human. METHODS: ABT was evaluated in a 7-week, open-label and randomized trial, combining with LPV/r. Twenty HIV-1-infected adults were assigned to two dose groups, receiving ABT (160 or 320 mg) given weekly and LPV/r given twice daily...
February 10, 2016: AIDS Research and Therapy
https://www.readbyqxmd.com/read/27052428/evaluation-of-pharmacokinetic-interactions-between-long-acting-hiv-1-fusion-inhibitor-albuvirtide-and-lopinavir-ritonavir-in-hiv-infected-subjects-combined-with-clinical-study-and-simulation-results
#2
Wanqiu Yang, Qingqing Xiao, Dan Wang, Cheng Yao, Jin Yang
1. A clinical study to assess the interactions between albuvirtide (320 mg) and lopinavir/ritonavir (400/100 mg) was conducted in 10 HIV-1-infected subjects. Because albuvirtide requires a long period to achieve steady state, and extended monotherapy may lead to early resistance, it is unethical to take albuvirtide alone to achieve steady state. Therefore, a population pharmacokinetic model was developed to predict steady-state concentration-time curve of solely administered albuvirtide. 2. When albuvirtide and lopinavir/ritonavir were co-administered, the plasma concentration of albuvirtide when the infusion ended (Cend) increased by about 34%, but the geometric mean ratios and 90% confidence intervals (90% CIs) of AUC(0-t) [1...
April 6, 2016: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://www.readbyqxmd.com/read/26865854/combination-of-long-acting-hiv-fusion-inhibitor-albuvirtide-and-lpv-r-showed-potent-efficacy-in-hiv-1-patients
#3
RANDOMIZED CONTROLLED TRIAL
Hongwei Zhang, Ronghua Jin, Cheng Yao, Tong Zhang, Meixia Wang, Wei Xia, Haiyan Peng, Xiaojuan Wang, Rongjian Lu, Changjin Wang, Dong Xie, Hao Wu
BACKGROUND: Long acting antiretroviral drugs represent a promising approach for chronic treatment of HIV infection. Here, we study the efficacy and safety of albuvirtide (ABT), an HIV-1 fusion inhibitor with a half life of 11-12 days in human. METHODS: ABT was evaluated in a 7-week, open-label and randomized trial, combining with LPV/r. Twenty HIV-1-infected adults were assigned to two dose groups, receiving ABT (160 or 320 mg) given weekly and LPV/r given twice daily...
2016: AIDS Research and Therapy
https://www.readbyqxmd.com/read/25428639/peptide-fusion-inhibitors-targeting-the-hiv-1-gp41-a-patent-review-2009-2014
#4
REVIEW
Dongmei Zhang, Wen Li, Shibo Jiang
INTRODUCTION: As the first peptide HIV fusion inhibitor targeting gp41, enfuvirtide (T20) was approved by the US FDA in 2003 as a salvage therapy for HIV/AIDS patients who failed to respond to the then existing antiretroviral therapeutics. However, its clinical application is limited by its relatively low potency, low genetic barrier to drug resistance and short half-life. Therefore, it is essential to develop new peptide HIV fusion inhibitors with improved antiviral efficacy, drug-resistance profile and pharmaceutical properties...
February 2015: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/24100879/the-antiretroviral-drug-pipeline-prospects-and-implications-for-future-treatment-research
#5
REVIEW
Charles Flexner, Michael Saag
PURPOSE OF REVIEW: A number of investigational antiretroviral drugs in clinical development could alter the future treatment landscape for resource-limited settings and contribute to optimized therapy for HIV infection. RECENT FINDINGS: Several nucleoside reverse transcriptase inhibitors (NRTIs) are in development, including festinavir (BMS-986001), a thymidine analogue similar to stavudine but with reduced potential for toxicity, CMX-157, a hexadecyloxypropyl conjugate of tenofovir and tenofovir alafenamide (GS-7340), a prodrug of tenofovir achieving much higher intracellular triphosphate concentrations with a lower dose than tenofovir disoproxil fumarate...
November 2013: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/23363694/new-and-investigational-antiretroviral-drugs-for-hiv-infection-mechanisms-of-action-and-early-research-findings
#6
REVIEW
Michael S Saag
Numerous investigational antiretroviral agents are in clinical development. Among them are festinavir (BMS986001), a thymidine analogue similar to stavudine with reduced potential for toxicity; GS-7340, a prodrug of tenofovir that achieves greater intracellular concentrations; MK-1439, a nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) that retains activity against common NNRTI-associated resistance mutations; and albuvirtide, a long-acting parenteral fusion inhibitor. Investigational integrase strand transfer inhibitors (InSTIs) include elvitegravir, recently approved by the US Food and Drug Administration (FDA) as part of a once-daily, single-tablet formulation with cobicistat/tenofovir/emtricitabine; dolutegravir, which maintains some activity against raltegravir- and elvitegravir-resistant mutants; and S/GSK1265744, which also maintains some activity against resistance mutations in the integrase gene and is being developed as a long-lasting parenteral agent...
December 2012: Topics in Antiviral Medicine
https://www.readbyqxmd.com/read/22403678/biophysical-property-and-broad-anti-hiv-activity-of-albuvirtide-a-3-maleimimidopropionic-acid-modified-peptide-fusion-inhibitor
#7
Huihui Chong, Xue Yao, Chao Zhang, Lifeng Cai, Sheng Cui, Youchun Wang, Yuxian He
Albuvirtide (ABT) is a 3-maleimimidopropionic acid (MPA)-modified peptide HIV fusion inhibitor that can irreversibly conjugate to serum albumin. Previous studies demonstrated its in vivo long half-life and potent anti-HIV activity. Here, we focused to characterize its biophysical properties and evaluate its antiviral spectrum. In contrast to T20 (Enfuvirtide, Fuzeon), ABT was able to form a stable α-helical conformation with the target sequence and block the fusion-active six-helix bundle (6-HB) formation in a dominant-negative manner...
2012: PloS One
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"